Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 7, 2013 - Issue
Submit an article Journal homepage
141
Views
21
CrossRef citations to date
0
Altmetric
Review

Advances in the proteomic discovery of novel therapeutic targets in cancer

Shanchun Guo1 Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Clark Atlanta University, Atlanta, GA, USA
,
Jin Zou2 Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USACorrespondence[email protected]
&
Guangdi Wang3 Research Centers in Minority Institutions Cancer Research Program, Xavier University of Louisiana, New Orleans, LA, USACorrespondence[email protected]
Pages 1259-1271 | Published online: 24 Oct 2013

Figures & data

Figure 1 Workflow of quantitative proteomic analysis of resistant cancer phenotypes, drug-treated cancer cells, and differentiated tumor tissues.

Abbreviations: TMT, tandem mass tags; HPLC, high-performance liquid chromatography; MS, mass spectrometry.
Figure 1 Workflow of quantitative proteomic analysis of resistant cancer phenotypes, drug-treated cancer cells, and differentiated tumor tissues.

Figure 2 Quantitative proteomic analysis in target discovery, validation, and drug development.

Abbreviations: Bio, biological; SILAC, stable isotope labeling by amino acids in cell culture; iTRAQ, isobaric tag for relative and absolute quantitation; TMT, tandem mass tag; prep, preparation.
Figure 2 Quantitative proteomic analysis in target discovery, validation, and drug development.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.